Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285610 | 0.95 | GRM4 (0.32) | S1PR1S1PR3LPAR3LPAR1LPAR2 | |
| SCHEMBL8742717 | 0.93 | LPAR3 (0.33) | S1PR1S1PR3LPAR3LPAR1LPAR2 | |
| SCHEMBL3280332 | 0.88 | LPAR3 (0.32) | S1PR1S1PR3LPAR3LPAR1LPAR2 | |
| SCHEMBL8743769 | 0.87 | LPAR3 (0.33) | S1PR1S1PR3LPAR3LPAR1LPAR2 | |
| SCHEMBL5705354 | 0.81 | ALDH1A1 (0.32) | — | |
| SCHEMBL6468999 | 0.81 | FFAR1 (0.38) | S1PR1S1PR3LPAR3LPAR1LPAR2 | |
| SCHEMBL3279503 | 0.81 | FFAR1 (0.34) | S1PR1S1PR3LPAR3LPAR1LPAR2 | |
| SCHEMBL3279884 | 0.81 | GRM4 (0.34) | — | |
| SCHEMBL6467870 | 0.79 | FFAR1 (0.41) | S1PR1S1PR3LPAR3LPAR1LPAR2 | |
| SCHEMBL6464982 | 0.79 | FFAR1 (0.41) | S1PR1S1PR3LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975300-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8642653-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, CETP | S1PR1 891/4885S1PR3 1087/4885LPAR3 1636/4885 |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | S1PR1 736/4885S1PR3 940/4885LPAR3 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.